Curis Inc. Regains Nasdaq Bid-Price Compliance; One-Year Monitor

What Happened

• Curis, Inc. announced in an 8-K filed July 30, 2026 that Nasdaq notified the company on July 24, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the bid-price rule).
• Nasdaq will place Curis under a Discretionary Panel Monitor for one year under Listing Rule 5815(d)(4)(A). The filing was signed by CFO Diantha Duvall.

Key Details

• Notice date: July 24, 2026; 8-K filed: July 30, 2026.
• Compliance restored for Nasdaq Listing Rule 5550(a)(2) (minimum bid-price requirement).
• One-year Discretionary Panel Monitor applies from July 24, 2026; during the monitor period Curis cannot submit a plan for cure under Rule 5810(c)(2) if a new deficiency arises, and Nasdaq staff will not grant additional time to regain compliance.
• If Curis fails to maintain any continued listing requirement during the monitor period, Nasdaq staff will issue a Delist Determination Letter and the company must promptly schedule a hearing (oral or written) with the Hearings Panel, which will consider Curis’s compliance history.

Why It Matters

• For investors, this means Curis remains listed on Nasdaq for now, but its listing is under closer scrutiny for the next year. The company faces a stricter process if another compliance issue occurs: no automatic cure period and a faster path to a delisting determination. The filing also includes the company’s standard forward-looking statements caution, noting there is no guarantee the company will remain listed if future deficiencies occur.